LORICRIN and psoriasis: The effects of IL‐38 on psoriasis development were demonstrated through IL‐38 injection into imiquimod‐induced psoriatic mice, showed down‐regulated levels of loricrin, CXCL8, CXCL20 and IL‐6, and ameliorated the manifestations, such as reduction of acanthosis and dermal inflammatory infiltrate.9